摘要
目的:探讨吲哚胺吡咯2,3-双加氧酶(IDO,一种具有免疫调节作用的酶)在肾细胞癌(RCC)患者中的作用。方法:在中南大学湘雅二医院诊断为RCC的患者40例,全部接受肾切除术。肾组织的免疫病理检查采用半定量方法评估。实时定量PCR(RT-qPCR)检测RCC与非肾癌肾组织IDO的mRNA水平。免疫组织化学的方法检测血管内皮细胞的IDO蛋白表达。同时依据IDO的mRNA水平计算出患者的Kaplan-Meier生存曲线。结果:RCC肿瘤组织中IDO mRNA的表达明显高于正常肾组织(P<0.001)。在RCC患者中,IDO高表达的患者比那些低IDO表达的患者具有明显较长的生存时间(P=0.01)。统计学分析显示:RCC肿瘤组织中IDO的水平和肿瘤增殖标志物Ki67之间呈负相关,IDO水平高的患者Ki67水平低,反之亦然(P<0.01)。结论:IDO可能作为预测RCC患者预后的生物标志物。
Objective： To explore the role ofindoleamine-pyrrole 2,3-dioxygenase （IDO）, an immunomodulatory enzyme, in renal cell carcinoma （RCC）. Methods： A total of 40 patients diagnosed as RCC in the Second Xiangya Hospital were included in this stud）n All patients received nephrectom）n The histopathological features of samples were assessed semi-quantitatively. IDO mRNA level in RCC and non-RCC renal tissues was determined by real-time quantitative PCR （RT-qPCR）. And the expression oflDO protein in endothelial cells was examined by immunohistochemistry; a Kaplan-Meier survival curves was calculated on the basis oflDO mRNA level. Results： Level of IDO mRNA in RCC samples was significantly higher than that in tumor-free samples with P〈0.001. Patients with high IDO expression had an significantly longer survival time than those with low IDO expression （P=0.01）. qhere was a statistically significant inverse correlation between IDO and proliferation marker Ki67. Patients with high IDO level were of low Ki67 level, and vice versa （P〈0.01）. Conclusion： IDO might be a prognostic biomarker for patients with RCC.
出处
《中南大学学报（医学版）》
CAS
CSCD
北大核心
2012年第7期649-655,共7页
Journal of Central South University ：Medical Science
